The isolation of endothelial progenitor cells (EPCs) derived from bone marrow (BM) was an outstanding event in the recognition of 'de novo vessel formation' in adults occurring as physiological and pathological responses. The finding that EPCs home to sites of neovascularization and differentiate into endothelial cells (ECs) in situ is consistent with 'vasculogenesis', a critical paradigm well described for embryonic neovascularization, but proposed recently in adults in which a reservoir of stem or progenitor cells contributes to vascular organogenesis. EPCs have also been considered as therapeutic agents to supply the potent origin of neovascularization under pathological conditions. This review provides an update of EPC biology as well as highlighting their potential use for therapeutic regeneration.
. Introduction
physiological or pathological neovascularization. The finding that EPCs home to sites of neovascularization and Tissue regeneration by somatic stem / progenitor cells differentiate into endothelial cells (ECs) in situ is conhas been recognized as a maintenance or recovery system sistent with 'vasculogenesis', a critical paradigm well of many organs in adult. The isolation and investigation of described for embryonic neovascularization, but recently these somatic stem / progenitor cells has described how proposed in adults in which a reservoir of stem / progenitor these cells contribute to postnatal organogenesis. On the cells contributes to post-natal vascular organogenesis. The basis of the regenerative potency, these stem / progenitor discovery of EPCs has therefore drastically changed our cells are expected to develop as a key strategy of therapeuunderstanding of adult blood vessel formation. The followtic applications for the damaged organs.
ing review provides an update of EPC biology as well as Recently endothelial progenitor cells (EPCs) have been highlighting their potential utility for therapeutic vascular isolated from adult peripheral blood (PB). EPCs are regeneration. considered to share common stem / progenitor cells with hematopoietic stem cells and have been shown to derive from bone marrow (BM) and to incorporate into foci of 2 . Post-natal neovascularization originally recognized to be constituted by the mechanism the autocrine, paracrine, and / or endocrine systems. Thus of 'angiogenesis', which is neovessel formation, operated the contemporary view of tissue regeneration is that by in situ proliferation and migration of preexisting neighboring differentiated ECs are relied upon for vascular endothelial cells. However, the isolation of EPCs resulted regeneration during a minor insult, whereas tissue specific in the addition of the new mechanism, 'vasculogenesis', or BM-derived stem / progenitor cells bearing EPCs / ECs which is de novo vessel formation by in situ incorporation, are important when an emergent vascular regenerative differentiation, migration, and / or proliferation of BM-deprocess is required (Fig. 1 ). rived EPCs [4] (Fig. 1 ). More recently, tissue specific stem / progenitor cells with the potency of differentiation into myocytes or ECs were isolated in skeletal muscle tissue of murine hindlimb, although the origin remains to 3 . Profiles of EPCs in adults be clarified [5] . This finding suggests that the origin of EPCs may not be limited to BM, e.g. tissue specific 3 .1. The evidence of circulating EPCs in adults stem / progenitor cells possibly provide 'in situ EPCs' as other sources of EPCs than BM.
In the embryo, evidence suggests that hematopoietic In the event of minor scale neovessel formation, i.e. stem cells (HSCs) and EPCs [8, 9] are derived from a slight wounds or burns, 'in situ preexisting ECs' causing common precursor (hemangioblast) [10, 11] . During empost-natal angiogenesis may replicate and replace the bryonic development, multiple blood islands initially fuse existing cell population sufficiently, as ECs exhibit the to form a yolk sac capillary network [12] , which provides ability for self-repair that preserves their proliferative the foundation for an arteriovenous vascular system that activity. Neovascularization through differentiated ECs, eventually forms following the onset of blood circulation however, is limited in terms of cellular life span (Hayflick [8] . The integral relationship between the cells which limit) and their inability to incorporate into remote target circulate in the vascular system (the blood cells) and those sites. In the case of large scale tissue repair, such as principally responsible for the vessels themselves (ECs) is patients who experienced acute vascular insult secondary suggested by their spatial orientation within the blood to burns, coronary artery bypass grafting (CABG), or acute islands; those cells destined to generate hematopoietic cells myocardial infarction [6, 7] , or in physiological cyclic are situated in the center of the blood island (HSCs) while organogenesis of endometrium [4] , BM-derived or in situ EPCs or angioblasts are located at the periphery of the EPC kinetics are activated under the influence of approblood islands. In addition to this arrangement, HSCs and priate cytokines, hormones and / or growth factors through EPCs share common antigens, including CD34, Vascular Fig. 1 . Post-natal neovascularization in the physiological or pathological events is consistent with neovessel formation contributed by angiogenesis and vasculogenesis at the various rates between their two mechanisms. Angiogenesis and vasculogenesis are due to the activations of in situ ECs and BM-derived or in situ EPCs, respectively.
endothelial growth factor receptor-2 (VEGFR2), Tie-2, differentiate immature EPCs or primitive HSCs from CD117, and stem cell antigen-1 (Sca-1) [13] .
circulating EPCs. [20] or growth factor-induced EPCs [24] . Gunsilius et al. investigated a chronic neovascularization [21] . Also, in the tumor neovascularizamyelogenous leukemia model and disclosed that BMtion, the range is approximately 35-45% higher than the derived EPCs contribute to postnatal neovascularization in former events [22] . The degree of EPC contribution to human [26] . Interestingly, in the report, BM-derived EPCs post-natal neovascularization is predicted to depend on could be detected even in the wall of quiescent vessels each neovascularizing event or disease.
without neovascularization events. This finding suggests that BM-derived EPCs may relate even to the turnover of 3 .
Isolation of EPCs in circulation
ECs consisting of quiescent vessels. Reyes et al. have recently isolated multipotent adult Under the current status, it is impossible to differentiate progenitor cells (MAPCs) from BM MNCs, differentiated 'immature EPCs' from primitive HSCs, as those cells them into EPCs and proposed MAPCs as an origin of share common surface markers, i.e. AC133, CD34, or EPCs [22] . These studies therefore provide evidence to VEGFR2 as described above. In circulation, the cell support the presence of BM-derived EPCs that take part in population with the capacity of differentiation to EPCs is neovascularization. Also, as described above, the existence considered to be included in the cell population expressing of 'in situ EPCs' as derived from tissue specific stem / AC133 and VEGFR2 markers in the subset of CD34 progenitor cells in murine skeletal muscle remains to be positive cells [15] . Circulating EPCs are constitutively investigated also in the other tissues [5] (Fig. 2) . expressing stem / progenitor markers, i.e. CD34 or VEGFR2 except AC133, and start expressing endothelial lineage specific markers, VE cadherin or E-selectin. On the 4 . EPC kinetics in adults other hand, following the commitment and differentiation to hematopoietic stem / progenitor cells, the surface 4 .1. EPC kinetics effected by endogenous agents markers of AC133 and VEGFR2 are extinguished. Such stem / progenitor cell markers do not express on the difThe incorporation of BM-derived EPCs into foci of ferentiated hematopoietic cells. Alternatively, kinds of physiological and pathological neovascularization has been surface markers are expressed to characterize individual demonstrated through various animal experiments. One hematopoietic cell populations. AC133 is a marker to well-established model that allows the detection of BM- derived EPCs includes transplanting wild-type mice with tion of BM-derived EPCs, we considered exogenous BM cells harvested from transgenic mice in which LacZ mobilization of EPCs as an effective means of augmenting expression is regulated by an EC lineage-specific promotthe resident population of EPCs / ECs. Such a strategy is er, flk-1 or Tie-2 (flk-1 / lacZ / BMT, Tie-2 / lacZ / BMT).
appealing for its potential to overcome the endothelial Using such mice, flk-1-or Tie-2-expressing endothelial dysfunction or depletion that may be associated with older, lineage cells derived from BM (EPCs) have been shown to diabetic, or hypercholesterolemic patients. Granulocyte localize to vessels during tumor growth, wound healing, macrophage colony-stimulating factor (GM-CSF) is well skeletal and cardiac ischemia, corneal neovascularization, known to stimulate hematopoietic progenitor cells and and endometrial remodeling following hormone-induced myeloid lineage cells, but has recently been shown to exert ovulation [4] . a potent stimulatory effect on EPC kinetics. The delivery Tissue trauma causes mobilization of hematopoietic of this cytokine induced EPC mobilization and enhanced cells as well as pluripotent stem or progenitor cells from neovascularization of severely ischemic tissues and de the hematopoietic system [32] . Consistent with the notion novo corneal vascularization [33] . that EPCs and HSCs share a common ancestry, recent data
The exact mechanism by which EPCs are mobilized to from our laboratory have shown that mobilization of BMthe peripheral circulation remains unknown, but may derived EPCs constitutes a natural response to tissue mimic aspects of embryonic development. Vascular endoischemia. The aforementioned murine BMT model also thelial growth factor (VEGF), critical for angio / vasprovided direct evidence of enhanced BM-derived EPC culogenesis in the embryo [34] [35] [36] , has recently been incorporation into foci of corneal neovascularization folshown to be an important stimulus of adult EPC kinetics. lowing the development of hindlimb ischemia [33] . This
Our studies carried out first in mice [37] and subsequently finding indicates that circulating EPCs are mobilized in patients undergoing VEGF gene transfer for critical limb endogenously in response to tissue ischemia and can or myocardial ischemia [38] established that a previously incorporate into neovascular foci to promote tissue repair. unappreciated mechanism by which VEGF contributes to These results in animals were recently confirmed by neovascularization is in part by mobilizing BM-derived human studies illustrating EPC mobilization in patients EPCs. Similar modulation of EPC kinetics has been following burns [6] , CABG, or acute myocardial infarction observed in response to other hematopoietic stimulators, [7] .
such as granulocyte-colony stimulating factor (G-CSF) and As previous studies demonstrated, endogenous mobilizastroma-derived factor-1 (SDF-1) [39] .
.2. EPC kinetics effected by exogenous agents
showing that the number and migratory activity EPC mobilization has recently been implicated not only of circulating EPCs inversely correlates with risk factors by natural hematopoietic or angiogenic stimulants but also for coronary artery disease, such as smoking, family by pharmacological agents. For instance, 3-hydroxy-3-history and hypertension [53] . On the basis of these methylglutaryl coenzyme A (HMG-CoA) reductase infindings, monitoring of BM-derived EPC kinetics in the hibitors (statins) are known to rapidly activate Akt sigpatients with vascular diseases is expected to be valuable naling in ECs, thereby stimulating EC bioactivity in vitro in the evaluation of lesion activity and / or therapeutic and enhancing angiogenesis in vivo [40] . Recent studies by efficacy. Dimmeler et al. and our laboratory have demonstrated a novel function of statins by mobilizing BM-derived EPCs through the stimulation of the Akt signaling pathway 5 . Therapeutic vasculogenesis [41] [42] [43] [44] . Therefore this newly appreciated role of statins, along with their already well-established safety and effica-5 .1. The potential of EPC transplantation cy on hypercholesterolemia, suggests that they can offer benefit in treating various forms of vascular diseases. On
The regenerative potential of stem / progenitor cells is the other hand, some antiangiogenic agents, i.e. angiostatin currently under intense investigation. In vitro, stem / or soluble flk-1, have been shown to inhibit BM-derived progenitor cells possess the capability of self-renewal and EPC kinetics, leading to tumor regression [45] , as BMdifferentiation into organ-specific cell types. When placed derived EPC kinetics is a critical factor for tumor growth, in vivo, these cells are then provided with the proper in terms of tumor neovascularization [46] . milieu that allows them to reconstitute organ systems. The novel strategy of EPC transplantation (cell therapy) may 4 .3. Clinical profile of EPC kinetics therefore supplement the classic paradigm of angiogenesis developed by Folkman and colleagues. Our studies indiThere is a strong body of evidence to suggest that cated that cell therapy with culture-expanded EPCs can impaired neovascularization results in part from diminsuccessfully promote neovascularization of ischemic tisished cytokine production. However, endogenous expressues, even when administered as 'sole therapy,' i.e. in the sion of cytokines is not the only factor leading to impaired absence of angiogenic growth factors. Such a 'supply-side' neovascularization. Diabetic or hypercholesterolemic aniversion of therapeutic neovascularization in which the mals-like clinical patients-exhibit evidence of dysfuncsubstrate (EPCs / ECs) rather than ligand (growth factor) tion in mature endothelial cells. While the cellular dysfunccomprises the therapeutic agent, was first demonstrated by tion does not necessarily preclude a favorable response to intravenously transplanting human EPCs to immunocytokine replacement therapy, the extent of recovery in deficient mice with hindlimb ischemia [25] . These findings limb perfusion in these animals fails to reach that of provided novel evidence that exogenously administered control animals; this suggests another limitation imposed EPCs rescue impaired neovascularization in an animal by a diminished responsiveness of EPCs / ECs [47] [48] [49] .
model of critical limb ischemia. Not only did the heteroThe aging characterized by impaired neovascularization logous cell transplantation improve neovascularization and [50, 51] might be associated with dysfunctional EPCs and blood flow recovery, but also led to important biological defective vasculogenesis. Indeed, preliminary results from outcomes-notably, the reduction of limb necrosis and our laboratory indicate that transplantation of BM (includauto-amputation by 50% in comparison with controls. A ing EPCs) from old mice into young mice led to minimal similar strategy applied to a model of myocardial ischemia neovascularization in a corneal micropocket assay, relative in the nude rat demonstrated that transplanted human EPCs to transplantation of young BM. We also demonstrated that localize to areas of myocardial neovascularization, difEPCs from older patients with clinical ischemia had ferentiate into mature ECs and enhance neovascularization. significantly less therapeutic effect in rescuing ischemic These findings were associated with preserved left venhindlimb of mice compared with those from younger tricular (LV) function and diminished myocardial fibrosis ischemic patients [52] . These studies provide evidence to [54] . Murohara et al. reported similar findings in which support an age-dependent impairment in vasculogenesis (as human cord blood-derived EPCs also augmented well as angiogenesis) that is heavily influenced by the EPC neovascularization in a hindlimb ischemic model of nude phenotype. Moreover, analysis of clinical data from older rats, followed by in situ transplantation [17] . patients at our institution disclosed a significant reduction More recently, other researchers have explored the in the number of EPCs at baseline, as well as that in therapeutic potential of freshly isolated human CD341 response to VEGF165 gene transfer [38] Similarly Kocher et al. attempted intravenous infusion of (vide infra), constitute major limitations of primary EPC freshly isolated human CD341 MNCs into nude rats with transplantation. Considering autologous EPC therapy, cermyocardial ischemia, and found preservation of LV functain technical improvements that may help to overcome the tion associated with inhibition of cardiomyocyte apoptosis primary scarcity of a viable and functional EPC population [55] . Thus two approaches of EPC preparation (i.e. both should include: (1) local delivery of EPCs, (2) adjunctive cultured and freshly-isolated human EPCs) may provide strategies (e.g. growth factor supplements) to promote therapeutic benefit in vascular diseases, but as described BM-derived EPC mobilization [33, 37] , (3) enrichment below, will likely require further optimization of techprocedures, i.e. leukapheresis or BM aspiration, or (4) niques to acquire the ideal quality and quantity of EPCs for enhancement of EPC function by gene transduction (gene EPC therapy (Fig. 3) .
modified EPC therapy, vide infra), (5) healthy human volunteers typically yields 5.0310 cells described above, allogenic EPCs derived from umbilical per 100 ml of blood on day 7. Our animal studies [25] cord blood or culture-expanded from human embryonic suggest that heterologous transplantation requires systemic stem cells [17, 56] , may be available as the sources 4 injection of 0.5-2.0310 human EPCs / g body weight of supplying EPCs. the recipient animal to achieve satisfactory reperfusion of an ischemic hindlimb. Rough extrapolation of these data to 5 .3. Gene modified EPC therapy human suggests that a blood volume of as much as 12 l may be necessary to obtain adequate numbers of EPCs to A strategy that may alleviate potential EPC dysfunction treat critical limb ischemia in patients. Therefore, the in ischemic disorders is considered reasonable, given the fundamental scarcity of EPCs in the circulation, combined findings that EPC function and mobilization may be with their possible functional impairment associated with a impaired in certain disease states. Genetic modification of variety of phenotypes in clinical patients, such as aging, EPCs to overexpress angiogenic growth factors, to enhance diabetes, hypercholesterolemia, and homocyst(e)inemia signaling activity of the angiogenic response, and to rejuvenate the bioactivity and / or extend the life span of EPCs have also been investigated in the cerebrovascular EPCs, can constitute such potential strategies.
field. Embolization of the middle cerebral artery in Tie2 / We have recently shown for the first time that genelacZ / BMT mice disclosed that the formation of new blood modified EPCs rescue impaired neovascularization in an vessels in the adult brain after stroke involves vasanimal model of limb ischemia [57] . Transplantation of culogenesis / EPCs [66] . Similar data were reported using heterologous EPCs transduced with adenovirus encoding gender-mismatched wild-type mice transplanted with BM human VEGF165 not only improved neovascularization from Green Fluorescein Protein transgenic mice [67] . and blood flow recovery, but also had meaningful bioHowever, whether autologous EPC transplantation would logical consequences, i.e. limb necrosis and auto-amputaaugment cerebral revascularization has yet to be examined. tion were reduced by 63.7% in comparison with controls.
To date, the role of EPCs in tumor angiogenesis has Notably, the dose of EPCs needed to achieve limb salvage been demonstrated by several groups. Davidoff [60, 61] could negative (non-committed) and CD117 positive BM cells augment neovascularization in ischemic tissue mainly can regenerate de novo myocardium and ECs and improve through the production of angiogenic growth factors and cardiac function when they were locally delivered into less through the differentiation of a portion of the cells into murine myocardial infarction model [68] . They also reEPCs / ECs in situ. Although there are no long-term safety ported that mobilization of BM cells by G-CSF and stem and efficacy data for local delivery of such cell population cell factor leads to a reduction in infarct size, improves mostly composed of inflammatory leukocytes, these stratecardiac function and decreases the mortality in this animal gies have already been applied to clinical patients in some model [69] . Jackson et al. showed that BM-derived stem institutions and preliminary results are expected soon.
cells (side population cells defined by dye exclusion) can differentiate into cardiomyocytes and ECs at a very low rate in murine cardiac reperfusion injury model following 6 . Other devices of EPCs for clinical application BMT [70] . These studies suggest a clinical use of BM for cardiovascular diseases other than EPCs / therapeutic vasEPCs have recently been applied to the field of tissue culogenesis. Given the extensive plasticity of BM cells engineering as a means of improving biocompatibility of differentiating into neural, hepatic and mesenchymal vascular grafts. Artificial grafts first seeded with autologlineages, BM-derived EPCs may also exhibit such a ous CD341 cells from canine BM and then implanted into potential, as seen in the report suggesting the transdifferenthe aortae were found to have increased surface endotiation of endothelial lineage cells into cardiomyocytes thelialization and vascularization compared with controls [71] . [62] . Similarly, when cultured autologous ovine EPCs were seeded onto carotid interposition grafts, the EPCseeded grafts achieved physiological motility and remained 7 . Conclusion patent for 130 days versus 15 days in non-seeded grafts [63] . Alternatively, as previously reported, the cell sheets As the concepts of BM-derived EPCs in adults and of cultured cardiomyocytes may be effective for the postnatal vasculogenesis are further established, clinical improvement of cardiac function in the damaged hearts, applications of EPCs to regenerative medicine are likely to i.e. ischemic heart disease or cardiomyopathy [64, 65] . The follow. To acquire the more optimized quality and quantity cell sheets consisting of cardiomyocytes with EPCs exof EPCs, several issues remain to be addressed, such as the pected to induce neovessels may be attractive, as blood development of a more efficient method of EPC purificasupply is essential to maintain the homeostasis of imtion and expansion, the methods of administration and planted cardiomyocytes in such cell sheets. senescence in EPCs. Alternatively, in the case of im-
